NCPE chief under fire for his 'cost-effectiveness' comment on life-saving drugs 

Michael Barry made his comments after a review into the approval of new medicines was announced — in the wake of Craig Coady's plea for Friedreich’s ataxia drug
Prof Michael Barry, the clinical director for the National Centre for Pharmacoeconomics (NCPE), made his 'value for money' comment on RTÉ on Sunday. File picture: Shane O'Neill/Coalesce

Prof Michael Barry, the clinical director for the National Centre for Pharmacoeconomics (NCPE), made his 'value for money' comment on RTÉ on Sunday. File picture: Shane O'Neill/Coalesce

Comments by the head of the committee that recommends to the HSE whether new drugs should be approved or not, about survival rates versus cost effectiveness, were "inappropriate" and caused "disgust" among campaigners, an Oireachtas committee has heard.

Director of the National Centre for Pharmacoeconomics (NCPE) Professor Michael Barry told RTÉ Radio 1's This Week on Sunday that he is opposed to early access to a new drug on a cost-effectiveness basis.

You have reached your article limit. Already a subscriber? Sign in

BLACK FRIDAY

Offer ends in:

Days
0
Hours
0
Minutes
0
Seconds
0
Black Friday subscription offer

More in this section

Politics

Newsletter

From the corridors of power to your inbox ... sign up for your essential weekly political briefing.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited